Dr. Febbo is responsible for developing and executing medical strategy to drive genomic testing into healthcare practice. Before joining Illumina, Dr. Febbo served as CMO of Genomic Health. Prior to his years at Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the UCSF, where his laboratory focused on using genomics to understand clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. Dr. Febbo holds an M.D. from UCSF. Completing his internal medicine residency at the Brigham and Women’s Hospital and fellowship in oncology at the Dana-Farber Cancer Institute. While an Attending Physician at Dana-Farber and Instructor at Harvard Medical School, he was a post-doctoral fellow at Dana-Farber and the Whitehead Institute Center for Genomic Research of MIT. In 2004, Dr. Febbo joined Duke University Medical Center’s Institute of Genome Sciences and Policy until his return to UCSF.